In this study (4-imidazolidine-4-one) derivative of naproxen was prepared and diagnosed, while the structural formula of this compound was confirmed using the (H-NMR, FTIR,13C-NMR) spectrum. (12) Rabbits of close weights were divided into two groups, the first group is the control group which consists of (4) Rabbits and the second group is the group that was injected with the compound, which was prepared and the number of (8) Rabbits. The first group was given the control group solvent (DMSO), the second group was injected with the compound (AB) and the dose (50 mg / kg) of body weight per rabbit. After 2 hours of the dose, a blood sample was drawn from each rabbit and the plasma was separated. A biochemical and enzymatic study of the variables was carried out. The measured variables included the activity of enzymes (cholinesterase, alanine transaminase, aspartate transaminase) and serum cholesterol concentration. The study proved that the compound has significantly inhibited the cholinesterase activity and can be used in the treatment of patients with Alzheimer's disease and increase the amount of neurotransmitter acetylcholine. Inhibiting cholinesterase inhibits the breakdown of the neurotransmitter and thus will perform the stimulation of the nervous system naturally, and effectively the compound did not significantly affect the activity of the enzyme glutamate oxaloacetate transaminase, glutamate pyruvate transaminase, while the cholesterol level in the rabbit serum had a significant effect.